Cancer Chemotherapy and Pharmacology

, Volume 73, Issue 1, pp 191–198

Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer

Authors

  • Seung Woo Yi
    • Department of Internal Medicine, Institute of GastroenterologyYonsei University College of Medicine
  • Dae Ryong Kang
    • Biostatistics Collaboration UnitYonsei University College of Medicine
  • Kyung Sik Kim
    • Department of SurgeryYonsei University College of Medicine
  • Mi Suk Park
    • Department of Diagnostic RadiologyYonsei University College of Medicine
  • Jinsil Seong
    • Department of Radiation OncologyYonsei University College of Medicine
  • Jeong Youp Park
    • Department of Internal Medicine, Institute of GastroenterologyYonsei University College of Medicine
  • Seung Min Bang
    • Department of Internal Medicine, Institute of GastroenterologyYonsei University College of Medicine
  • Si Young Song
    • Department of Internal Medicine, Institute of GastroenterologyYonsei University College of Medicine
  • Jae Bock Chung
    • Department of Internal Medicine, Institute of GastroenterologyYonsei University College of Medicine
    • Department of Internal Medicine, Institute of GastroenterologyYonsei University College of Medicine
Original Article

DOI: 10.1007/s00280-013-2340-5

Cite this article as:
Yi, S.W., Kang, D.R., Kim, K.S. et al. Cancer Chemother Pharmacol (2014) 73: 191. doi:10.1007/s00280-013-2340-5

Abstract

Purpose

There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC).

Methods

We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival.

Results

Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85–49.30) in CCRT group and 13.29 weeks (95 % CI 10.42–16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed.

Conclusions

Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.

Keywords

Biliary tract cancerConcurrent chemoradiationGB cancerLocally advanced

Copyright information

© Springer-Verlag Berlin Heidelberg 2013